H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older

An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Biological: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation

• Study Type: Interventional
• Enrollment (Actual): 91
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Fukuoka City, Japan, 812-0025
    • PS Clinic
  • Osaka City, Japan, 532-0003
    • Osaka Pharmacology Clinical Research Hospital (OPHAC Hospital)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant is 65 years or older at the time of screening.
• Participant is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination.
• Participant is physically and mentally capable of participating in the study.
• Participant is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

• Participant has a history of infection with H5N1 virus or a history of vaccination with an H5N1 influenza vaccine.
• Participant is at high risk of contracting H5N1 influenza infection (e.g., poultry workers).
• Participant currently has or has a history of a significant cardiovascular (including hypertension), respiratory (including asthma), metabolic, neurological (including Guillain-Barré Syndrome and acute disseminated encephalomyelitis), hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder.
• Participant has any inherited or acquired immunodeficiency.
• Participant has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to: systemic or inhaled corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs.
• Participant has a history of severe allergic reactions or anaphylaxis.
• Participant has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating.
• Participant has received a blood transfusion or immunoglobulins within 90 days prior to study entry.
• Participant has donated blood or plasma within 30 days prior to study entry.
• Participant has received any influenza or any live vaccine within 4 weeks or any other inactivated vaccine within 2 weeks prior to vaccination in this study.
• Participant has a functional or surgical asplenia.
• Participant has a known or suspected problem with alcohol or drug abuse.
• Participant has been exposed to an investigational product (IP) within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
• Participant is a family member or employee of the investigator.
• Participant has any other condition that disqualifies his/her participation in the study in the opinion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Influenza Vaccine; One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.	Biological: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Co-Primary Evaluation of Immunogenicity by Single Radial Hemolysis (SRH) Assay: Number of participants with antibody response to vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after second vaccination defined as hemolysis area measured by SRH assay ≥25mm^2	Day 43 (42 days after first vaccination, 21 days after second vaccination)
Co-Primary Evaluation of Immunogenicity by SRH Assay: Number of participants demonstrating seroconversion 21 days after the second vaccination	'Seroconversion' is defined as either a ≥25mm^2 hemolysis area after the vaccination in case of a negative prevaccination sample (≤4mm^2) or a ≥50% increase in hemolysis area if the prevaccination sample is >4mm^2.	Day 43 (42 days after first vaccination, 21 days after second vaccination)
Co-Primary Evaluation of Immunogenicity by SRH Assay: Fold increase of antibody response 21 days after the second vaccination as compared to baseline		Day 43 (42 days after first vaccination, 21 days after second vaccination)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of Immunogenicity by SRH Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after the first and 180 days after the second vaccination defined as SRH area ≥25mm^2	Days 22 and 202
Evaluation of Immunogenicity by SRH Assay: Number of participants demonstrating seroconversion 21 days after the first and 180 days after the second vaccination	'Seroconversion' is defined as either a ≥25mm^2 hemolysis area after the vaccination in case of a negative prevaccination sample [≤4mm^2] or a ≥50% increase in hemolysis area if the prevaccination sample is >4mm^2.	Days 22 and 202
Evaluation of Immunogenicity by SRH Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination		Days 22, 43 and 202
Evaluation of Immunogenicity by SRH Assay: Fold increase of antibody response 21 days after the first and 180 days after the second vaccination as compared to baseline		Days 22 and 202
Evaluation of Immunogenicity by Microneutralization (MN) Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after the first and 21 and 180 days after the second vaccination defined as MN titer ≥ 1:20	Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Number of participants demonstrating seroconversion 21 days after the first and 21 and 180 days after the second vaccination	'Seroconversion' is defined as a four-fold or greater increase in titer as compared to baseline.	Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination		Days 22, 43 and 202
Evaluation of Immunogenicity by MN Assay: Fold increase of antibody response 21 days after the first and 21 and 180 days after the second vaccination as compared to baseline		Days 22, 43 and 202
Evaluation of Immunogenicity by Hemagglutination Inhibition (HI) Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)	Associated with protection 21 days after the first and 21 and 180 days after second vaccination defined as HI titer ≥ 1:40	Days 22, 43 and 202
Evaluation of Immunogenicity by HI Assay: Number of participants demonstrating seroconversion 21 days after the first and 21 and 180 days after the second vaccination	'Seroconversion' is defined as a 4-fold or greater increase in HI titer as compared to baseline	Days 22, 43 and 202
Evaluation of Immunogenicity by HI Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination		Days 22, 43 and 202
Evaluation of Immunogenicity by HI Assay: Fold increase of antibody response 21 days after the first and 21 and 180 days after the second vaccination as compared to baseline		Days 22, 43 and 202
Frequency and severity of injection site and systemic reactions until 21 days after the first and second vaccinations		Through study day 43
Evaluation of Immunogenicity by MN Assay: Number of participants demonstrating either ≥4-fold titer increase compared to baseline if above detection limit OR ≥ 20 titer after vaccination if baseline titer is below detection limit		Days 22, 43 and 202
Number of participants with fever, malaise or shivering with onset within 7 days after the first and second vaccinations		Days 1-8 and days 22-29
Frequency and severity of all adverse events (AEs) observed during the entire study period		Throughout the study period- 8 months

Collaborators and Investigators

• Sponsor: Ology Bioservices
• Investigators: Study Director: Nirjhar Chatterjee, MD, Baxter Innovations GmbH

Study record dates

Study Major Dates

• Study Start: March 1, 2013
• Primary Completion (Actual): June 1, 2013
• Study Completion (Actual): October 1, 2013

Study Registration Dates

• First Submitted: January 17, 2013
• First Submitted That Met QC Criteria: January 22, 2013
• First Posted (Estimate): January 23, 2013

Study Record Updates

• Last Update Posted (Estimate): October 9, 2015
• Last Update Submitted That Met QC Criteria: October 7, 2015
• Last Verified: April 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human
• Other Study ID Numbers: 811201